Shingo Takano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/755269/publications.pdf

Version: 2024-02-01

48 papers

1,014 citations

361296 20 h-index 30 g-index

58 all docs 58 docs citations

58 times ranked 1800 citing authors

#	Article	IF	CITATIONS
1	Inducing substances for chondrogenic differentiation of dental pulp stem cells in the conditioned medium of a novel chordoma cell line. Human Cell, 2022, 35, 745.	1.2	2
2	Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy. Brain Tumor Pathology, 2021, 38, 149-155.	1.1	7
3	Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis. BMC Neurology, 2021, 21, 282.	0.8	7
4	Involvement of the optic pathway and outcome of visual function in patients with neurohypophyseal germ cell tumor. Acta Neurochirurgica, 2021, 163, 3191-3199.	0.9	0
5	Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of Pl3 \hat{K}^3 inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathology, 2020, 37, 41-49.	1.1	37
6	GCT-38. RELAPSE PATTERNS OF INTRACRANIAL GERMINOMAS BEFORE AND AFTER ENDOSCOPIC ERA. Neuro-Oncology, 2020, 22, iii335-iii335.	0.6	0
7	Pure germinoma occurring 11Âyears after total pineal mature teratoma removal: a case report and review of the literature. Child's Nervous System, 2019, 35, 2423-2426.	0.6	2
8	IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS. Neuro-Oncology Advances, 2019, 1, ii11-ii12.	0.4	0
9	ANGI-05 PATHOGENESIS OF RESISTANCE (MIMICRY AND CO-OPTION) TO ANTI-ANGIOGENIC TREATMENT FOR GLIOBLASTOMA. Neuro-Oncology Advances, 2019, 1, ii5-ii5.	0.4	O
10	Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Cancer Science, 2019, 110, 401-407.	1.7	20
11	Combined Endoscopic Endonasal and Transoral Surgery for a Chordoma in the Whole Clivus With Marked Caudal Extension. Operative Neurosurgery, 2018, 14, 463-464.	0.4	2
12	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. World Neurosurgery, 2018, 112, e69-e73.	0.7	26
13	Clinical significance of diseaseâ€specific <i><scp>MYD</scp>88</i> mutations in circulating <scp>DNA</scp> in primary central nervous system lymphoma. Cancer Science, 2018, 109, 225-230.	1.7	57
14	Anatomical variations of the torcular Herophili: macroscopic study and clinical aspects. Anatomical Science International, 2018, 93, 464-468.	0.5	14
15	Prognostic analysis of patients who underwent gross total resection of newly diagnosed glioblastoma. Journal of Clinical Neuroscience, 2018, 50, 172-176.	0.8	14
16	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell, 2018, 33, 1004-1016.e5.	7.7	52
17	Problem and Handling of Anti-angiogenic Therapy for Glioblastoma: Vessel Co-option and Vascular Mimicry. Japanese Journal of Neurosurgery, 2018, 27, 723-735.	0.0	0
18	The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas. International Journal of Oncology, 2017, 50, 515-524.	1.4	12

#	Article	IF	CITATIONS
19	Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. Journal of Neuro-Oncology, 2017, 133, 277-285.	1.4	39
20	Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. Journal of Clinical Neuroscience, 2017, 40, 115-119.	0.8	5
21	<i>MYD88</i> (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. British Journal of Haematology, 2017, 177, 492-494.	1,2	42
22	Longâ€term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clinical Endocrinology, 2017, 86, 207-213.	1,2	17
23	Intradiploic Arachnoid Cyst with Meningothelial Hyperplasia: A Case Report. NMC Case Report Journal, 2017, 4, 19-22.	0.2	1
24	A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 41-46.	0.3	10
25	Basics of Photodynamic Therapy for Malignant Brain Tumors. Japanese Journal of Neurosurgery, 2016, 25, 905-911.	0.0	0
26	Hyperfractionated high-dose proton beam radiotherapy for clival chordomas after surgical removal. British Journal of Radiology, 2016, 89, 20151051.	1.0	18
27	Immunohistochemistry on IDH $1/2$, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathology, 2016, 33, 107-116.	1.1	47
28	Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas. Brain Tumor Pathology, 2015, 32, 169-175.	1,1	10
29	Improvement of Long-term Results with Neoadjuvant Chemotherapy andÂRadiotherapy for Central Nervous System Germinoma. World Neurosurgery, 2015, 84, 846-854.	0.7	5
30	Neuroendoscopy Followed by Radiotherapy in Cystic Craniopharyngiomas—a Long-Term Follow-Up. World Neurosurgery, 2015, 84, 1305-1315.e2.	0.7	26
31	Intraparenchymal brain lesion biopsy guided by a rigid endoscope and navigation system., 2015, 6, 149.		5
32	Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. OncoTargets and Therapy, 2014, 7, 1551.	1.0	14
33	Malignant Lymphoma in the Parasellar Region. Case Reports in Medicine, 2014, 2014, 1-5.	0.3	12
34	Correlations of Vascular Architecture and Angiogenesis with Pituitary Adenoma Histotype. International Journal of Endocrinology, 2014, 2014, 1-12.	0.6	17
35	Interferon- \hat{I}^2 inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. International Journal of Oncology, 2014, 45, 1837-1846.	1.4	31
36	Brain metastasis from papillary thyroid carcinomas. Molecular and Clinical Oncology, 2013, 1, 817-819.	0.4	16

3

#	Article	IF	CITATIONS
37	Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. Journal of Neuro-Oncology, 2012, 108, 361-373.	1.4	45
38	Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathology, 2012, 29, 73-86.	1.1	39
39	Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathology, 2011, 28, 115-123.	1.1	96
40	Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. Journal of Neuro-Oncology, 2010, 99, 177-185.	1.4	23
41	Molecular Therapeutic Targets for Glioma Angiogenesis. Journal of Oncology, 2010, 2010, 1-11.	0.6	62
42	Anti-angiogenic and Immunomodulatory Effect of the Herbal Medicine "Juzen-taiho-to" on Malignant Glioma. Biological and Pharmaceutical Bulletin, 2005, 28, 2111-2116.	0.6	46
43	Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathology, 2004, 21, 69-73.	1.1	35
44	Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: Effects on tumor growth and angiogenesis in human glioblastoma xenografts. Neuro-Oncology, 2003, 5, 1-7.	0.6	20
45	Localization of gelatinase activities in glioma tissues by film in situ zymography. Brain Tumor Pathology, 2001, 18, 145-150.	1.1	10
46	Facial Spasm and Paroxysmal Tinnitus Associated with an Arachnoid Cyst of the Cerebellopontine Angle â€"Case Reportâ€". Neurologia Medico-Chirurgica, 1998, 38, 100-103.	1.0	23
47	Central Nervous System Metastasis from Gallbladder Carcinoma. Neurologia Medico-Chirurgica, 1991, 31, 782-786.	1.0	23
48	Slow Reduction in Ventricular Size after Removal of Choroid Plexus Papilloma. Neurologia Medico-Chirurgica, 1988, 28, 604-609.	1.0	1